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Virus-Induced Neuronal
Apoptosis Blocked by the Herpes
Simplex Virus Latency-Associated
Transcript
Guey-Chuen Perng,1 Clinton Jones,2 Janice Ciacci-Zanella,2
Melissa Stone,2 Gail Henderson,2 Ada Yukht,1 Susan M. Slanina,1
Florence M. Hofman,3 Homayon Ghiasi,1,4
Anthony B. Nesburn,1,4 Steven L. Wechsler1,4*
Latent infections with periodic reactivation are a common outcome after acute
infection with many viruses. The latency-associated transcript (LAT ) gene is
required for wild-type reactivation of herpes simplex virus (HSV). However, the
underlying mechanisms remain unclear. In rabbit trigeminal ganglia, extensive
apoptosis occurred with LAT ⫺ virus but not with LATⴙ viruses. In addition, a
plasmid expressing LAT blocked apoptosis in cultured cells. Thus, LAT promotes
neuronal survival after HSV-1 infection by reducing apoptosis.
After primary infection of the eye, herpes simplex virus–type 1 (HSV-1) establishes a lifelong latent infection in neurons of the trigeminal ganglia (TGs), with sporadic periods of
reactivation and recurrent disease. Recurrent
ocular HSV (HSV-1 and HSV-2) is a leading
cause of corneal blindness resulting from an
infectious agent. Recurrent genital HSV is a
serious sexually transmitted disease. Latent
HSV infections affect 70 to 90% of adults.
During latency, a single viral gene—the
LAT gene—is abundantly transcribed (1, 2).
LAT is essential for the efficient reactivation of
HSV from latency (3). The primary LAT is 8.3
kb and overlaps the important immediate early
gene ICP0 in an antisense direction. Thus, it
was proposed that LAT may function through
an antisense mechanism (1, 2). However, the
first 1.5 kb of LAT alone is sufficient for wildtype levels of spontaneous reactivation (4), and
this region does not overlap any known HSV-1
gene. LAT may enhance the establishment or
maintenance of latency (5– 8), thereby increasing the pool of latently infected neurons, which
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in turn results in increased levels of spontaneous and/or induced reactivation (9). Although
studies with one LAT ⫺ mutant have suggested
that a LAT-related function may suppress productive-cycle gene expression during acute and
latent infection of mouse trigeminal ganglia
(10, 11), no evidence was presented to show
that LAT caused these effects directly, rather
than through a pleiotropic effect. We recently
reported on a mutant containing a partial deletion of LAT in which neurovirulence was increased (12). This finding suggested that LAT
might protect neurons from being killed by
HSV-1, thereby allowing HSV-1 to establish
latency in more neurons.
To determine whether neurons were being
protected by LAT, we used dLAT2903, a LAT
null mutant derived from the McKrae strain of
HSV-1 (3). This mutant contains a deletion that
includes the LAT promoter and the 5⬘ half of the
stable 2-kb LAT; this deletion (nucleotides
⫺161 to ⫹1667) results in the absence of LAT
RNAs and does not overlap or interfere with the
ICP0 transcript. Like most LAT mutants,
dLAT2903 has no known deficits other than
being impaired for reactivation from latency.
Thus, dLAT2903 is wild type for replication in
mouse and rabbit eyes, HSV-1–induced eye
disease, replication in TGs, and neurovirulence
(3). However, with dLAT2903, large numbers
of neurons positive for TUNEL (terminal deoxynucleotidyl transferase–mediated deoxyuridine triphosphate nick-end labeling) were seen
in rabbit TGs on day 7 after infection (Table 1;
70% of sections, 100% of TGs), whereas in this
experiment TUNEL-positive cells were not de-
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visualized with the FLAG-specific mAb M2 and TRITCcoupled anti-mouse IgG.
Plasmid pWS30 (22) was used for inactivation of
cagA. For construction of a cagE⫺ insertion mutant,
the Hp 26695 chromosomal region (position 574639
to 579587) was amplified by polymerase chain reaction (PCR). The PCR fragment was cloned in pMin1,
mutated by a TnMax transposon derivative as described [A. F. Kahrs et al., Gene 167, 53 (1995)], and
used for transformation of strain P12, resulting in the
cagE⫺ mutant. For construction of P12⌬cagA, region
579021 –to 579905 (cagA-upstream) and 583483 to
584934 (cagA-downstream) of the Hp 26695 genome were amplified by PCR with 18-nucleotide
flanking sequences as primers. Fragments were
cloned into pBluescript Xho I–Bam HI sites, separated
by an aphA-3 gene cassette. For complementation,
the cagA gene of 26695 was amplified by PCR and
cloned into the pHel2 vector (Xho I–Bam HI) (15).
The FLAG-tag (Sigma) sequence was fused to the
cagA-downstream primer (5⬘-CGGGATCCT TACT TGTCATCGTCGTCCT TGTAGTCAGAT T T TTGGAAACCACCT T-3). The 18-nucleotide cagA upstream primer
starts at position 579701 (19). Transformation of Hp
strains was performed as described [R. Haas et al.,
Mol. Microbiol. 8, 753 (1993)].
AGS cells (1 ⫻ 107) were infected with Hp P12,
incubated for 4 hours (37°C, 5% CO2), washed 5⫻
with PBS*, and lysed in 500 l of modified RIPA
buffer [50 mM tris-HCl (pH 7.4), 150 mM NaCl, 1 mM
EDTA, 1% NP-40, 0.25% Na-deoxycholate, 1 mM
PMSF, 1 mM orthovanadate, 1 M leupeptin,1 M
pepstatin] (1 hour, 4°C, gentle shaking). The lysate
was cleared (15,000 rpm, 4°C, 10 min) and the
protein content adjusted to 3 mg/ml with PBS*.
AK257 (1.7 g/ml) was added to a total volume of
900 l; after 1 hour at 4°C, 40 l of Protein G–agarose (Roche) was added and the mixture incubated
for a further 2 hours at 4°C. After a short centrifugation step (10 s, 6.000g) the supernatant was discarded, and beads were washed four times with 1 ml
of PBS* and suspended in 40 l of sample solution.
The COOH-terminal part of CagA was produced as a
fusion protein with MS2-polymerase and an NH2terminal His6-tag by using the Escherichia coli expression vector pEV40 [ J. Pohlner et al., Gene 130,
121 (1993)]. The fusion protein was expressed and
purified by Ni2⫹–nitrilotriacetic acid affinity chromatography by standard procedures and used to immunize a rabbit to obtain antiserum AK257. AK175 was
generated by immunization of a rabbit with whole
heat-killed Hp bacteria. Immunoblotting was performed and alkaline phosphatase (AP)–coupled protein A was used to visualize the antibody bound by
decomposition of nitro blue tetrazolium.
After standard infection of AGS cells with Hp strains
(10), cells were washed three times with PBS⫹, harvested with a cell scraper, and treated with PBS*
containing 0.05% (w/v) saponin for 10 min at room
temperature. Cellular debris and bacteria were separated from the soluble material by centrifugation (5
min, 6000g) and 0.2-m pore diameter filtration of
the supernatant. Pellets were resuspended in 30 l of
sample solution, and supernatants were precipitated
with chloroform-methanol as described [D. Wessel
and U. I. Flügge, Anal. Biochem. 138, 141 (1984)] and
resuspended in 30 l of sample solution. Equal
amounts (8 l) of probes were loaded on 6 or 10%
polyacrylamide gels.
D. Heuermann and R. Haas, Mol. Gen. Genet. 257,
519 (1998).
Available at www.motif.genome.ad.jp/.
The sequence of the P12cagA gene was obtained by
PCR amplification of the complete gene fragment
from corresponding chromosomal DNA and sequencing of the cloned genes by primer walking.
ATCC43526 CagA (GenBank accession number
2073135), CagA sequences of J99 (18) and 26695
(19).
R. A. Alm et al., Nature 397, 176 (1999).
J.-F. Tomb et al., Nature 388, 539 (1997).
E. E. Galyov, S. Håkansson, A. Forsberg, H. Wolf-Watz,
Nature 361, 730 (1993).
O. Ilan et al., EMBO J. 18, 3241 (1999).

tected in TGs from rabbits infected with wildtype McKrae. Only small amounts of TUNELpositive cells were detected in TGs from
dLAT2903R, a rescued virus in which the deleted LAT region was restored. The results for
dLAT2903-infected rabbits were significantly
different from those for the wild type–
infected and dLAT2903R-infected rabbits
[P ⬍ 0.001 for sections, P ⬍ 0.05 for TGs;
analysis of variance (ANOVA), Tukey comparison test for peak days of apoptosis]. Representative photomicrographs are shown in Fig. 1.
More rabbits were infected (five rabbits per
group) and killed on day 7 after infection to
study additional aspects of enhanced apoptosis
in rabbits infected with the LAT ⫺ virus (Table
2). Fifty sections per group (five sections from
each of 10 TGs) were examined. Extensive
apoptosis (⬎25% TUNEL-positive neurons)
was observed in 66% of the sections from
dLAT2903 (LAT ⫺)–infected rabbits, versus
only 4% of the sections from uninfected rabbits or rabbits infected with wild-type McKrae or dLAT2903R (P ⬍ 0.001; ANOVA,
Tukey posttest). When all TGs with extensive
apoptosis in at least one section were counted
(Table 2), 90% of TGs from rabbits infected
with dLAT2903 met this criterion, versus
only 10 to 20% of TGs from uninfected
rabbits or rabbits infected with wild-type
McKrae or dLAT2903R (P ⬍ 0.01).
When we counted all TG sections with any
amount of apoptosis in neurons, this threshold
was met by 74% of the sections from rabbits
infected with dLAT2903; this was significantly
higher than for TGs from uninfected rabbits or
rabbits infected with wild-type McKrae or
dLAT2903R (P ⬍ 0.001) (Table 2). All 10 TGs
from rabbits infected with dLAT2903 were
positive according to this criterion, whereas
only 5 of 10 TGs from rabbits infected with
wild-type McKrae or dLAT2903R were positive (P ⫽ 0.03) (Table 2). The sporadic low
levels of apoptosis detected in rabbit TGs in-

fected with wild-type McKrae were expected
because HSV-1 can induce apoptosis (13–16).
The results of these TUNEL assays suggest
that apoptosis was more likely, by a factor of 2
to 16, in rabbit TGs infected with the LAT ⫺
mutant. Because HSV-1 can induce apoptosis
in infected tissue culture cells (13–16), we suspect that the apoptotic neurons detected in TGs
by TUNEL were a direct result of the HSV-1
infection. However, because on day 7 (the time
of peak apoptosis) viral antigens can no longer
be detected in these TGs by immunofluorescent
staining (17), it is possible, but unlikely, that
some of the apoptosis may be due to a bystander effect.
A newly devised method for detection of
apoptosis in tissue sections was used to confirm
the TUNEL results. TG sections obtained 7
days after infection were stained with an antibody to poly(ADP-ribose) polymerase (PARP)
(Anti-PARP p85 fragment pAb kit; Promega,
Madison, WI), as described by the manufacturer. Anti-PARP p85 detects caspase-3 cleavage
fragments of PARP, a hallmark of apoptosis
(18 –20). Representative photomicrographs are

shown in Fig. 2. Extensive cleavage of PARP
was detected in five of six TGs from LAT ⫺infected rabbits (⬎25% of neurons) but in none
of the four TGs from wild-type–infected rabbits
(P ⫽ 0.048, Fisher exact test). All six LAT ⫺
TGs contained detectable levels of cleaved
PARP staining, versus only one of four TGs
from rabbits infected with wild-type virus (P ⫽
0.03). To further confirm the similarity of the
TUNEL and anti-PARP p85 results, we prepared seven pairs of sections, each pair from a
different TG. One section of each pair was
stained for TUNEL; the other section was
stained for PARP p85. A correlation was seen
between the percentage of positively stained
neurons on the TUNEL and anti-PARP p85
sections (R2 ⫽ 0.62, P ⫽ 0.04; linear regression; P ⬍ 0.05 indicates that the R2 value was
unlikely to have occurred by chance). Confirmation of the TUNEL results by anti-PARP
p85 staining indicates that most of the TUNELpositive cells were due to apoptosis rather than
another mechanism of cell death or reaction
with viral DNA ends. Thus, LAT appeared to
decrease HSV-1–induced apoptosis in rabbit

Table 1. Apoptosis in rabbit TGs. Rabbits were infected with wild-type HSV-1 McKrae, dLAT2903 (LAT–),
or dLAT2903R (LATⴙ) in both eyes (2 ⫻ 105 plaque-forming units per eye), as described (3). On the days
indicated after infection, two rabbits were killed per group. TGs were harvested and sectioned, and five
sections per TG (20 sections per group at each time point) were stained by the TUNEL assay that detects
DNA ends produced during apoptosis (Klenow-FragEL DNA fragmentation detection kit; Oncogene,
Cambridge, MA) as described by the manufacturer. Sections were read by light microscopy by two
individuals who had no knowledge of the groups and were considered positive for apoptosis if one or
more neurons were clearly positive. A TG was considered positive if one or more of its sections were
positive. For each TG, the sections used were obtained from different areas spanning the TG.
Criterion
Sections with apoptotic neurons (%)
dLAT2903
dLAT2903R
McKrae
TGs with apoptotic neurons (%)
dLAT2903
dLAT2903R
McKrae

Day 3

Day 7

Day 10

Day 14

5
0
0

70
0
0

10
20
0

5
5
0

0
0
0

100
25
0

25
25
0

25
25
0
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Fig. 1. Representative photomicrographs of TUNEL-stained TG sections (upper and lower rows represent two different experiments).
Rabbits were infected, then killed 7
days after infection; TGs were harvested and sections were stained
for apoptosis by TUNEL, as described in Table 1. (A) and (D), uninfected; (B) and (E), McKrae-infected; (C) and (F), dLAT2903 (LAT ⫺)–
infected. In (A) to (C), positive
staining is brown, counterstaining is
blue-green; magnification, ⬃⫻150.
In (D) to (F), positive staining is
brown, counterstaining is green;
magnification, ⬃⫻300. In (C), nonneuronal cells (apparently infiltrating immune cells), as well as neurons, show strong staining for apoptosis. In (F), brown dots in the
nucleus of large neurons indicate a
positive signal.
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Fig. 3. In vitro inhibition of apoptosis by a LAT plasmid. IMR-90 cells (A), CV-1 cells (B), or neuro-2A cells
(C) were cotransfected with 1 g of pCMV-␤-gal (a ␤-galactosidase expression plasmid) and 5 g of
APALAT (5). APALAT contains an Apa I–Apa I LAT restriction fragment (LAT nucleotides 301 to 2659)
inserted into pBABE Puro, a mammalian expression vector containing a retrovirus LTR, Poly(A) addition
signals, and the puromycin resistance gene regulated by the SV40 early promoter. Procedures for
calcium phosphate transfection and maintenance of cultures were as described (26). Twenty-four hours
after transfection, 10 M C6-ceramide (Calbiochem, San Diego, CA) (23–25) or 25 M fumonisin B1
(FB1) (26, 27) were added to IMR-90 and CV-1 cultures, and 15 M etoposide (Sigma) was added to
neuro-2A cultures. After 48 hours, ␤-gal⫹ cells were identified by staining the fixed cells with Bluo-gal
(Gibco-BRL) for 24 hours; ␤-gal⫹ cells were counted in five fields. The number of ␤-gal⫹ cells in control
cultures treated with phosphate-buffered saline represents 100% survival. Data are averages from four
independent experiments. Cells were cotransfected with pCMV-␤-gal and APALAT (APALAT ), pCMV␤-gal and the empty expression plasmid instead of APALAT (pBABE Puro), or pCMV-␤-gal and a plasmid
expressing the baculovirus CpIAP (inhibitor of apoptosis) gene instead of APALAT (CpIAP). Similar results
were obtained with a LAT restriction fragment not containing a Poly(A) signal.
Table 2. Rabbits were infected and TGs harvested 7 days after infection. Five well-spaced sections were
stained for apoptosis and examined from each of 10 TGs per group (50 sections per group), except for
the uninfected control group, in which only 47 sections were examined.
Criterion

dLAT2903

dLAT2903R

Sections with extensive apoptosis
TGs with extensive apoptosis
Sections with any apoptotic neurons
TGs with any apoptotic neurons

33/50 (66%)
9/10 (90%)
37/50 (74%)
10/10 (100%)

2/50 (4%)
1/10 (10%)
11/50 (22%)
5/10 (50%)

TGs on day 7 after infection.
To more directly test the hypothesis that
LAT has an antiapoptotic activity, we used a
quantitative assay (21, 22) in which cells are
cotransfected with a ␤-galactosidase expression
plasmid ( pCMV-␤-gal) and an expression plasmid containing the gene of interest, in the presence of an inducer of apoptosis. If the gene of
interest (in this case, LAT ) reduces apoptosis,
the number of ␤-gal⫹ cells will be higher.
Apoptosis was induced by the sphingoid base
C6-ceramide (23–25), the mycotoxin fumonisin
B1 (FB1) (26, 27), or the anticancer drug etoposide. Primary human lung cells (IMR-90),

1502

McKrae
2/50 (4%)
2/10 (20%)
8/50 (16%)
5/10 (50%)

Control
2/47 (4%)
1/10 (10%)
17/47 (36%)
10/10 (100%)

monkey kidney cells (CV-1), and murine neuroblastoma cells (neuro-2A cells) were used for
these studies.
An Apa I–Apa I LAT restriction fragment
(nucleotides 301 to 2659 of the 8.3-kb primary
LAT ) containing the entire stable 2-kb LAT
region from HSV-1 strain KOS (5) was inserted
into pBABE Puro, a mammalian expression
vector containing a retrovirus long terminal repeat (LTR), polyadenylate [Poly(A)] addition
signals, and the puromycin resistance gene regulated by the SV40 early promoter. The resulting plasmid (APALAT) was cotransfected into
the respective cells along with pCMV-␤-gal.

IMR-90 and CV-1 cells were subsequently
treated with C6-ceramide or FB1 and neuro-2A
cells with etoposide. Relative to cultures cotransfected with the empty pBABE Puro plasmid, the LAT-containing plasmid increased cell
survival in all cultures (as judged by the number
of ␤-gal⫹ cells) regardless of the agent used to
induce apoptosis (Fig. 3) (P ⬍ 0.0001;
ANOVA, Tukey posttest). Although the baculovirus antiapoptotic gene CpIAP (28) appeared
to inhibit apoptosis slightly more efficiently
than did LAT, the differences were not significant (P ⬎ 0.05).
Ceramide-induced apoptosis is blocked by
activating protein kinase C (23, 25), whereas
blocking the tumor necrosis factor pathway
(TNF/FAS) inhibits FB1-induced apoptosis
(26, 29). Etoposide inhibits topoisomerase II,
thus leading to higher levels of DNA damage
and p53-dependent apoptosis (13, 14, 30).
The ability of LAT to block apoptosis induced
by each of these agents therefore suggests
that LAT interferes with a downstream effector of apoptosis that is common to many
apoptotic pathways. In addition, the ability of
the APALAT fragment to block apoptosis
mapped this function to within a region comprising only 28% of the primary LAT. The
ability of this region to promote efficient
establishment and subsequent reactivation
from latency (5) strengthens the likelihood
that LAT’s antiapoptosis function plays an
important role in the latency reactivation cycle. The antiapoptotic activity of LAT did not
appear to be HSV-1 strain specific, because
we saw this activity with strain McKrae–
derived viruses and strain KOS LAT.
Previous studies have reported that under
different conditions, herpes simplex virus can
induce or inhibit apoptosis (15, 31, 32). At
least two other viral genes, ICP27 and US3,
can protect certain cells against virus-induced
apoptosis in tissue culture (31, 32). Our results show that LAT can suppress apoptosis of
neurons (either in vivo or in vitro) and that
this function may explain the importance of
LAT in herpes simplex virus latency and reactivation. Interestingly, we recently found
that the latency-related (LR) gene of bovine
herpes virus (BHV-1) also inhibits apoptosis
in transient transfection assays (33). BHV-1
and HSV-1 are only distantly related. The
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Fig. 2. Photomicrographs of TG sections stained with anti-PARP p85
(magnification, ⬃⫻300). Rabbits
were infected, then killed 7 days
after infection; TGs were harvested
and sections were stained for apoptosis using the Anti-PARP p85
fragment pAb kit (Promega). Brown
dots in the nucleus and cytoplasm
of large neurons indicate positive
staining. Counterstaining is bluegreen. Representative photomicrographs are shown. (A) Uninfected cells; (B) wild-type McKrae–infected cells; (C) dLAT2903 (LAT ⫺)–infected cells.

BHV-1 LR and the HSV-1 LAT have greatly
different sizes and little or no sequence similarity. Although the BHV-1 LR antiapoptosis
function correlates with expression of an LR
protein (33), the LAT antiapoptosis function
may be mediated by the LAT RNA, because
LAT does not appear to encode a protein (34 ).
Our results suggest that LAT promotes neuronal survival after HSV-1 infection by reducing
apoptosis. This hypothesis is supported by studies indicating that LAT ⫺ mutants establish latency less efficiently than does the wild type (5,
6, 35, 36) and that a mutant expressing an
altered LAT has increased neurovirulence (12).
In general, stress is associated with reactivation
and increased corticosteroid levels. Because corticosteroids induce apoptosis (37, 38), stress and
viral gene expression during reactivation may
induce apoptosis. Because LAT facilitates reactivation (3, 39, 40), inhibition of apoptosis by
LAT would increase the probability that productive infection (i.e., productive reactivation from
latency) succeeds. Whether reactivation was
successful or not, LAT ⴙ neurons may have a
better chance to survive and resume latency.
Thus, a LAT antiapoptosis function could allow
LAT to enhance reactivation by (i) enhancing the
establishment and maintenance of latency,
thereby providing more latently infected neurons in which future reactivations could occur;
(ii) facilitating productive reactivation by protecting against apoptosis in neurons in which
reactivation occurs; and (iii) facilitating the resumption of latency after a reactivation insult by
protecting neurons against apoptosis.
It is unlikely that LAT is the only factor
that promotes neuronal survival, because
terminally differentiated neurons must have
a well-devised mechanism to prevent programmed cell death. Furthermore, LAT may
have additional mechanisms by which it
enhances reactivation. Nonetheless, our results strongly suggest that suppressing apoptosis is an important mechanism by
which LAT enhances HSV-1 reactivation.
In addition, the ability of LAT to prevent
HSV-1–induced apoptosis may be important in preventing the virus from causing
extensive neuronal damage and subsequent
neuronal disorders.
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Porphyrin and Phthalocyanine
Antiscrapie Compounds
Suzette A. Priola,* Anne Raines, Winslow S. Caughey
The transmissible spongiform encephalopathies (TSEs) are fatal, neurodegenerative diseases for which no effective treatments are available. The likelihood
that a bovine form of TSE has crossed species barriers and infected humans
underscores the urgent need to identify anti-TSE drugs. Certain cyclic tetrapyrroles (porphyrins and phthalocyanines) have recently been shown to inhibit
the in vitro formation of PrP-res, a protease-resistant protein critical for TSE
pathogenesis. We now report that treatment of TSE-infected animals with three
such compounds increased survival time from 50 to 300%. The significant
inhibition of TSE disease by structurally dissimilar tetrapyrroles identifies these
compounds as anti-TSE drugs.
The TSEs are a group of rare, fatal neurodegenerative diseases that include scrapie in sheep,
bovine spongiform encephalopathy (BSE) in
cattle, chronic wasting disease in deer and elk,
and Creutzfeldt-Jakob disease (CJD) in humans.
The onset of the BSE epidemic in cattle in Great
Britain raised concerns that humans could be at
risk through exposure to contaminated cattle
by-products. In 1996, a previously unknown
form of CJD (variant CJD or vCJD) was identified in young people in Great Britain (1). The
hypothesis that the most likely cause of vCJD
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was exposure to BSE-contaminated materials
has since been supported by several different
studies (2). At present, over 40 cases of vCJD
have been confirmed, and there is some concern
that the number of cases could be on the rise (3).
Thus, with the potential exposure of millions of
people to BSE and the onset of vCJD, the need
for effective anti-TSE drugs has become acute.
A critical event in TSE pathogenesis is the
conversion of the normal protease-sensitive
host prion protein, PrP-sen, to a partially protease-resistant form (PrP-res) that is closely associated with disease pathogenesis. Studies
have shown that there is a close correlation
between compounds that inhibit PrP-res formation in vitro and compounds that inhibit TSE
disease (4). Therefore, PrP-res is an obvious
target for therapeutic intervention. The conversion of PrP-sen to PrP-res involves changes in
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